Physician profile
Thomas S Lin
NPI 1861421349
$3,749.04
in general payments reported to CMS, 2019-2025
14 companies · $886 in 2025
The $886 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $890 · 2020: $103 · 2021: $253 · 2022: $583 · 2023: $469 · 2024: $565 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $749.07 | 2019-2025 | Vemlidy, Livdelzi |
| Astrazeneca Pharmaceuticals LP | $551.32 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $507.87 | 2019-2025 | Ozempic, Wegovy |
| Amarin Pharma, INC. | $381.37 | 2019-2020 | |
| Glaxosmithkline, LLC. | $351.72 | 2022-2024 | Arexvy |
| Ironwood Pharmaceuticals, INC | $239.58 | 2019 | |
| Amgen INC. | $236.03 | 2023-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $153.22 | 2022-2025 | |
| Medtronic, INC. | $146.66 | 2023 | Percept PC Brainsense |
| Otsuka America Pharmaceutical, INC. | $135.17 | 2019-2021 | |
| Lilly USA, LLC | $132.64 | 2022-2023 | Mounjaro |
| Pfizer INC. | $74.84 | 2024 | |
| Abbvie INC. | $71.22 | 2021 | |
| Esperion Therapeutics, INC. | $18.33 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.